文献速递甲状腺疾病

通过非放射性高通量筛选方法鉴定和表征高活性、同工酶选择性的I型脱碘酶抑制剂

Identification and Characterization of Highly Potent and Isoenzyme-Selective Inhibitors of Deiodinase Type I via a Nonradioactive High-Throughput Screening Method.
PubMed 文献 · Thyroid · 2025-04-02

研究基于Sandell-Kolthoff反应建立半自动高通量筛选方法,从69,344种低分子量化合物中筛选I型脱碘酶(DIO1)抑制剂。共鉴定出15种DIO1选择性化合物(IC50 < 1 µM),活性强于丙硫氧嘧啶(PTU),其中13种受试化合物中有8种能在完整细胞中抑制DIO1。这些新型抑制剂可作为研究甲状腺激素调节和开发抗甲状腺功能亢进策略的先导化合物。

要点

  • 建立基于Sandell-Kolthoff反应的384孔板高通量筛选方法,筛选69,344种化合物。
  • 鉴定出15种DIO1选择性化合物(IC50 < 1 µM),活性强于PTU。
  • 13种受试化合物中有8种能在完整细胞中抑制DIO1。

核心结论

  • 成功应用基于SK反应的高通量筛选,鉴定了具有纳摩尔IC50值的新型、强效、选择性DIO1抑制剂。
  • 部分化合物能在完整细胞中抑制细胞内DIO1。
  • 这些新型化合物在研究甲状腺激素调节、解析DIO1酶结构和开发构效关系方面具有巨大潜力。
  • 新型抑制剂可作为开发对抗甲状腺功能亢进策略的先导化合物。

研究设计与样本

  • 采用基于Sandell-Kolthoff反应的半自动高通量筛选方法,在384孔板中筛选69,344种低分子量化合物的DIO1抑制效果。
  • 对初筛命中化合物进行手动验证筛选(298种化合物),并优先选择26种化合物全面表征其DIO1选择性抑制作用。
  • 在5 nM-20 µM浓度范围内评估化合物对三种DIO同工酶酶制剂的抑制效果。
  • 采用基于SK反应的新方案检测细胞培养上清液,并评估DIO1过表达HEK293细胞中的细胞内脱碘酶活性。

主要发现

  • 高通量筛选将436种(<1%)化合物标记为命中,包括已知DIO1抑制剂如PTU和染料木素。
  • 基于298种化合物的验证筛选,优先选择了26种化合物进行全面表征。
  • 鉴定出15种DIO1选择性化合物(IC50 < 1 µM),比真正的DIO1选择性抑制剂PTU更有效。
  • 13种受试化合物中有8种能够在完整细胞中抑制DIO1。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: Deiodinase type I (DIO1) is crucial in maintaining thyroid hormone (TH) balance. It converts the prohormone thyroxine (T4) to the active triiodothyronine (T3) and degrades T3 to inactive 3,3'-diiodothyronine (3,3'-T2). It also acts on reverse T3 (rT3) and sulfated TH metabolites, thus contributing to TH elimination. Upregulation of DIO1 is linked to hyperthyroid conditions such as Graves' disease and autonomous thyroid adenoma, making it a promising target for pharmacological intervention. The adverse side effects of the antithyroid drug propylthiouracil (PTU), used in clinics to treat hyperthyroidism due to its thyroid peroxidase- and DIO1-blocking action, highlight the need for novel and potent DIO1-selective inhibitors. Methods: Using a semiautomatic high-throughput screening (HTS) assay based on the Sandell-Kolthoff (SK) reaction in 384-well plates, we screened 69,344 low-molecular-weight compounds for DIO1-inhibitory effects. Shortlisted hits underwent detailed manual characterization, where we evaluated the potency and isoenzyme specificity by assessing their DIO-inhibitory effects on enzyme preparations from all three DIO isoenzymes, over a wide concentration range (5 nM-20 µM). To evaluate the DIO1 inhibitory effects in intact cells, we applied a novel protocol based on the SK reaction to cell culture supernatants and assessed the intracellular deiodinase activity in DIO1 overexpressing HEK293 cells. Results: The robust HTS assay flagged 436 (<1%) of the screened compounds as hits, also including known DIO1 inhibitors such as PTU and genistein. Based on a validation screen of 298 compounds, we prioritized 26 compounds to comprehensively characterize their DIO1-selective inhibition. We identified 15 DIO1-selective compounds (IC50 < 1 µM), more potent than the bonafide DIO1-selective inhibitor PTU. Additionally, 8 of the 13 tested compounds were found capable of inhibiting DIO1 in intact cells. Conclusions: With a successful SK-reaction-based HTS application, we identified novel, potent, and selective inhibitors of DIO1 with nanomolar IC50 values. Furthermore, we successfully showed that some of these compounds were also capable of inhibiting intracellular DIO1 in intact cells. These novel compounds hold immense potential in studying TH modulation, deciphering DIO1 enzyme structure, and developing structure-activity relationships. Furthermore, our novel inhibitors act as lead compounds in developing strategies to combat hyperthyroidism.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Sane R, Seyffarth C, Kleissle S, et al. Identification and Characterization of Highly Potent and Isoenzyme-Selective Inhibitors of Deiodinase Type I via a Nonradioactive High-Throughput Screening Method. Thyroid. 2025. PMID: 40170637. doi:10.1089/thy.2025.0036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。